Status:
UNKNOWN
Location of Lesions Responsible for Blood Loss in the Gastrointestinal (GI) Tract
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Iron Deficiency Anemia
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this study is to identify the prevalence, nature and location of lesions in the GI tract that may contribute to iron deficiency anaemia and compare diagnostic yied of the upper GI magne...
Detailed Description
Iron deficiency anaemia (IDA) affects 2-5% of men and post-menopausal women (1). It is thought to occur as a consequence of gastrointestinal blood loss in the majority of cases. Studies suggest that g...
Eligibility Criteria
Inclusion
- Male and female patients aged 18 years and over and up to but not exceeding 80 years
- Patients presenting with IDA whom require gastroscopy and colonoscopy as per national guidelines (1)
Exclusion
- Patients who have contraindications to gastroscopy or colonoscopy
- Patients under the age of 18 years
- Patients over the age of 80 years
- Active vomiting
- Patients with a permanent pacemaker, implantable cardioverter-defibrillator or REVEAL device
- Patients with any electronic/magnetic/mechanically controlled devices e.g. sacral nerve stimulators, bladder stimulators
- Patients with dysphagia, odynophagia or known swallowing disorder
- Patients with known Zenker's diverticulum
- Patients with suspected bowel obstruction or bowel perforation
- Patients with prior bowel obstruction
- Patients with gastroparesis or known gastric outlet obstruction
- Patients with known Crohn's disease
- Patients who are taking daily non-steroidal anti-inflammatory drugs (excluding prophylactic doses of aspirin) for more than six months
- Patients who have received abdominopelvic radiotherapy treatment
- Patients with a history of GI tract surgery (Billroth I, Billroth II, Oesophagectomy, gastrectomy or bariatric procedure)
- Patients that are pregnant or lactating
- Patients with altered mental status that would limit their ability to swallow
- Patients with allergy to conscious sedation, polyethylene glycol or metoclopramide
- Patients unwilling to swallow the capsule
- Patients with known dementia affecting ability to consent
- Patients who are unable to understand or speak English
- Patients unable to provide written informed consent
Key Trial Info
Start Date :
April 12 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2022
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT04840433
Start Date
April 12 2021
End Date
December 31 2022
Last Update
August 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital
Shatin, New Territories, Hong Kong